DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects.

A Comprehensive Review of Epidemiology, Risk Factors, and Treatment Strategies. Advances in Breast Cancer Research, 14, 1-15. doi: 10.4236/abcr.2025.141001 . Noncommunicable diseases like various ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...

Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 435 Skirkanich Hall, Philadelphia, Pennsylvania 19104, United States ...

In the introduction to their paper, the researchers detail how research in acute myeloid leukemia, breast ... cancer therapies. This innovative approach marks a paradigm shift in cancer treatment.

Although everyone’s CLL journey is different, there tend to be shared milestones that can give patients a sense of progress, as well as resilience, when navigating treatment options. Here’s what ...

A: Every year we are improving the curative treatment options we have for specific ... in the curative setting for hormonally driven breast cancer and 2) antibody drug conjugates.